Prosecution Insights
Last updated: October 02, 2026

Examiner: WRIGHT, SARAH C

Tech Center 1600 • Art Units: 1619

This examiner grants 42% of resolved cases

Analysis

Sarah C. Wright examines applications in Art Unit 1619 of Tech Center 1600. Her record includes 570 resolved cases and an allowance rate of 41.6%. The prosecution timeline is relatively long, with a median of 1254 days to allowance. These figures suggest that applicants in this art unit should be prepared for a thorough and potentially extended examination process. The 41.6% allowance rate indicates that the examiner maintains a high standard for patentability.

The most striking data point is the interview lift of 46.0%. This suggests that while the initial allowance rate is moderate, an interview nearly doubles the likelihood of success. For practitioners in this art unit, requesting an interview appears to be an essential tactical step to overcome rejections. The 1254 days to allowance highlights the importance of using every available tool, such as the 46.0% interview lift, to advance the case. The 570 resolved cases show that the examiner has a significant history of managing complex biological or chemical applications.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

41.6%
Allow Rate
-18.4% vs TC avg
624
Total Applications
+46.0%
Interview Lift
1254
Avg Prosecution Days
Based on 570 resolved cases, 2023–2026

Rejection Statute Breakdown

1.2%
§101 Eligibility
9.5%
§102 Novelty
56.3%
§103 Obviousness
16.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18807099 GELS AND RELATED METHODS FOR TREATING FISTULAS Non-Final OA Boston Scientific Scimed, Inc.
17980199 PERSONAL CARE COMPOSITION PRESERVATIVES LEVEL OPTIMIZATION Final Rejection The Procter & Gamble Company
15617399 NOVEL WOUND-HEALING-ENHANCING DEVICES Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18716721 DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOTHERAPEUTIC AGENT Non-Final OA Ohio State Innovation Foundation
18810852 COMPOSITION COMPRISING GLYCOLIPID, TAURATE SURFACTANT, AND AMINO ACID SURFACTANT Non-Final OA L'OREAL
18552336 EMULSION WITH NEUTRALIZED WATER-SOLUBLE SCREENING AGENT, NONVOLATILE NONPHENYLATED SILICONE OIL, FILM-FORMING POLYMER AND LINEAR POLYOXYALKYLENATED POLYDIMETHYLMETHYLSILOXANE EMULSIFIER Final Rejection L'OREAL
18005775 COSMETIC SUNSCREEN COMPOSITION, PROCESS FOR MANUFACTURING A COSMETIC SUNSCREEN COMPOSITION AND USE OF A COSMETIC SUNSCREEN COMPOSITION Non-Final OA L'OREAL
17787104 COMPOSITION COMPRISING A DISPERSION OF POLYMER PARTICLES IN A NON-AQUEOUS MEDIUM, A CATIONIC POLYMER AND AN ANIONIC POLYMER Non-Final OA L'OREAL
17601252 EMULSION COMPOSITION COMPRISING ULTRAVIOLET WAVELENGTH CONVERSION SUBSTANCE AND ORGANIC OILY PHASE THICKENER Non-Final OA Shiseido Company, Ltd.
18318100 Sunscreen Compositions and Methods of Use Non-Final OA Colgate-Palmolive Company
18194527 Skin Care Compositions Non-Final OA Colgate-Palmolive Company
18042484 Personal Care Compositions Final Rejection Colgate-Palmolive Company
17926009 COSMETIC Non-Final OA SHIN-ETSU CHEMICAL CO., LTD.
17747569 TEMPLATE PARTICLES WITH MICROPORES AND NANOPORES Non-Final OA ILLUMINA, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month